News
F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results